抑制c-Abl通过改善小鼠皮下脂肪胰岛素敏感性减轻饮食诱导的肥胖
本文在高脂饮食(HFD)诱导的肥胖小鼠和肥胖人群中分析c-Abl表达,并通过脂肪组织条件性敲除c-Abl及使用c-Abl抑制剂尼洛替尼干预,观察体质量、脂肪量、糖耐量和胰岛素耐量变化。结果显示,抑制c-Abl可改善胰岛素敏感性、减轻HFD诱导的体质量增加、高血糖和高胰岛素血症,并降低脂肪量,机制可能涉及减少HFD触发的胰岛素抵抗及增加皮下脂肪脂联素。
要点
- 肥胖人群和HFD诱导的肥胖小鼠皮下脂肪中c-Abl高表达。
- 脂肪组织条件性敲除c-Abl可改善胰岛素敏感性并减轻HFD诱导的体质量增加、高血糖和高胰岛素血症。
- 尼洛替尼可降低HFD喂养小鼠脂肪量并改善胰岛素敏感性,机制可能与增加皮下脂肪脂联素有关。
核心结论
- 作者认为c-Abl在饮食诱导的肥胖调控中具有新的生物学作用,其机制是改善皮下脂肪的胰岛素敏感性,并提示c-Abl可能成为治疗代谢性疾病的新靶点。
研究设计与样本
- 研究先以蛋白质印迹和定量PCR分析肥胖人群及HFD喂养小鼠不同脂肪组织中c-Abl的表达。
- 利用Fabp4-Cre在脂肪组织条件性敲除c-Abl基因(Abl1),6周龄小鼠分别给予普通饮食(CD)或HFD。
- 年龄匹配的野生型小鼠接受c-Abl抑制剂尼洛替尼或溶媒处理,并暴露于CD或HFD,随后分析体质量、脂肪量、葡萄糖耐量和胰岛素耐量。
- 采用组织学染色、ELISA和生化分析阐明生理与分子信号变化细节。
主要发现
- c-Abl在肥胖人群和HFD诱导的肥胖小鼠的皮下脂肪中高表达。
- 脂肪组织条件性敲除c-Abl改善胰岛素敏感性,并减轻HFD诱导的体质量增加、高血糖和高胰岛素血症。
- 尼洛替尼处理显著降低HFD喂养小鼠的脂肪量并改善胰岛素敏感性。
- 生化分析提示,抑制c-Abl通过减少HFD触发的胰岛素抵抗并增加皮下脂肪中的脂联素来改善全身胰岛素敏感性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: High-energy diets are among the main causes of the global epidemic of metabolic disorders, including obesity and type 2 diabetes. The mechanisms of high-energy-diet-induced metabolic disorders are complex and largely unknown. The non-receptor tyrosine kinase c-Abl plays an important role in adipogenesis in vitro but its role in vivo in the regulation of metabolism is still elusive. Hence, we sought to address the role of c-Abl in diet-induced obesity and obesity-associated insulin resistance. METHODS: The expression of c-Abl in different fat tissues from obese humans or mice fed a high-fat diet (HFD) were first analysed by western blotting and quantitative PCR. We employed conditional deletion of the c-Abl gene (also known as Abl1) in adipose tissue using Fabp4-Cre and 6-week-old mice were fed with either a chow diet (CD) or an HFD. Age-matched wild-type mice were treated with the c-Abl inhibitor nilotinib or with vehicle and exposed to either CD or HFD, followed by analysis of body mass, fat mass, glucose and insulin tolerance. Histological staining, ELISA and biochemical analysis were used to clarify details of changes in physiology and molecular signalling. RESULTS: c-Abl was highly expressed in subcutaneous fat from obese humans and HFD-induced obese mice. Conditional knockout of c-Abl in adipose tissue improved insulin sensitivity and mitigated HFD-induced body mass gain, hyperglycaemia and hyperinsulinaemia. Consistently, treatment with nilotinib significantly reduced fat mass and improved insulin sensitivity in HFD-fed mice. Further biochemical analyses suggested that c-Abl inhibition improved whole-body insulin sensitivity by reducing HFD-triggered insulin resistance and increasing adiponectin in subcutaneous fat. CONCLUSIONS/INTERPRETATION: Our findings define a new biological role for c-Abl in the regulation of diet-induced obesity through improving insulin sensitivity of subcutaneous fat. This suggests it may become a novel therapeutic target in the treatment of metabolic disorders.
引用
- Wu R, Sun JG, Wang JQ, et al. c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice. Diabetologia. 2017. PMID: 28074253. doi:10.1007/s00125-016-4202-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。